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Background: Prostate cancer patients with rectal involvement are rare, and the factors associated with the survival
of these patients are yet to be elucidated.
Patients and methods: We collected data on patients who were admitted to our hospital for prostate cancer in
the last thirteen years and of those in studies in the literature. The associations of clinical characteristics with
survival were evaluated using Cox regression models.
Results: This study included 94 patients (5 admitted to our hospital and 89 from studies in the literature) of
prostate cancer with rectal involvement. 11 patients in the group of synchronous rectal involvement at first cancer
diagnosis (n = 58) and 23 patients in the group of metachronous diagnosis of rectal involvement (n = 29) died at
the latest follow up. The estimated overall survival rate (% ± SE) at 1, 3, and 5 years were 68.3 ± 5.3%, 54.4 ± 7.2%,
and 38.1 ± 11.1%, respectively. In the Cox univariate analysis, Asian prostate cancer (p = 0.001) was associated with
better survival, while rectal bleeding (p = 0.043), metachronous presentation of development of rectal involvement
(p = 0.000), prior hormonal therapy (p = 0.000) and extrarectal metastases (p = 0.054) were associated with poor
survival. In multivariate analysis, prior hormone therapy (HR = 14.540, p = 0.000) and rectal bleeding (HR = 2.195,
p = 0.041) retained independent poor prognostic values. There were 13 patients survived for more than 3 years,
the longest survival time was 96 months. Total pelvic extenteration (TPE) combined with hormonal therapy in 12
hormone-untreated prostate cancer give us six of thirteen long-term survivors for more than 3 years in this series.
Conclusions: Our findings suggest that rectal involvement does not necessarily predict a worse outcome when
presenting as a previously hormone-untreated disease and that the prognosis was worse when presenting as a
hormone relapsed disease. Prior hormone therapy and rectal bleeding were associated independently with a
significantly poor overall survival in prostate cancer patients with rectal involvement. TPE combined with hormonal
therapy appears to confer better overall survival in hormonally untreated patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1604504118106105.
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Prostate cancer (PCa) is the most common malignancy in
Western countries and the second leading cause of cancer-
related deaths in males [1-3]. In China, the incidence of
prostate cancer has increased dramatically over the past
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reproduction in any medium, provided the orlifestyle changes [4]. According to the recent statistics in
China, PCa is the 7th most common cancer in males, and
its incidence rose to 11 per 105 in the year 2008 [5]. Despite
improvements in diagnosis, surgical techniques, and che-
motherapies, most deaths of PCa patients occur due to dis-
ease progression and metastasis.
Metastatic disease to the bones and lymph nodes has
long been recognized as the most typical pattern of
extraprostatic tumor spread [6]. Prostate cancer with
rectal involvement has only rarely been reported and re-
mains poorly understood [7-10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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were admitted to our institution because of this rare
tumor over the past 13 years, and thoroughly reviewed
the literature for individually documented cases of pros-
tate cancer with rectal involvement to comprehensively
analyze patient and tumor characteristics, survival and
prognostic factors in these rare tumors.Patients and methods
Patient population
The patients examined in this study were enrolled in the
following manner. First, we studied the data on all pa-
tients who were diagnosed with rectal involvement of
prostate adenocarcinoma at the Tianjin Medical University
Cancer Center and Institute between January 1990 and
April 2013. These cases were retrospectively reviewed on
the basis of histological examination of a surgical specimen
or tissue biopsy. Rectal cancer patients with metastasis to
the prostate or with synchronous and metachronous
adenocarcinoma of the prostate and rectum were excluded.
In all cases in our cohort, the diagnosis of prostate cancer
with rectal involvement was determined by rectal biopsy
and/or prostate biopsy or postoperative histology. Most of
them were confirmed with immunohistochemical staining
for prostate specific antigen (PSA) or prostatic acid phos-
phatase (PAP). This study was carried out in accordance
with the principles of the Helsinki Declaration and
approved by the Institutional Review Board of Tianjin
Medical University Cancer Institute and Hospital. Written
informed consent was obtained from all of the study
participants.
Second, a systematic search of the literature was per-
formed to identify all relevant articles dealing with prostate
cancer with rectal involvement. First, a computerized
search was made of the electronic databases PubMed (1990
to 2013) and google scholar (1990 to 2013) with the follow-
ing Mesh headings and key words: “prostate/prostate neo-
plasms/prostate cancer” in combination with “rectum or
rectal involvement or invading”. The search was exploded
using the “related articles” term in PubMed. The abstracts
of all identified articles were studied and selection was
based on their relevance for the subject. The reference lists
of selected articles were then screened systematically for
additional studies of interest. No restrictions for language
were applied. Articles containing duplications of case de-
scriptions were excluded. In addition, patients with prostate
special pathological type, including sarcoma, squamous cell
carcinoma,small cell carcinoma and so on were excluded
because of the different tumor biology in comparison with
prostate adenocarcinoma. We reviewed the titles to include
case reports or review articles on or case series of prostate
cancer invading rectum. Altogether, 35 reference articles
were suitable for further review. All 35 articles werereviewed to identify patients with prostate cancer invading
rectum.
Clinical data
Clinical data including patient demographics, clinical
characteristics, extent of disease (extrarectal Pca metas-
tases), type of rectal involvement, treatment modalities,
and follow-up on these patients were extracted by 2 au-
thors, then crosschecked to ensure accuracy, and finally
entered into a database. Some factors had higher missing
values because secondary data were collected in the lit-
erature review. Clinical data at our institute were deter-
mined by reviewing their medical records. Type of rectal
involvement was defined according to the criteria de-
scribed in the literature [11,12]. Overall survival was de-
fined as the time from the date of diagnosis of prostate
cancer with rectal involvement to the date of death. In
the absence of confirmation of death, survival time was
censored at the last date the patient was known to be
alive.
Statistical analyses
Data on patient demographics, tumor characteristics, ex-
tent of disease, treatment modalities were summarized
using descriptive statistics. The associations between
these factors and survival were evaluated using the uni-
variate Cox regression models. The hazard ratio of death
and its 95% confidence interval were calculated for each
factor. Multivariate Cox proportional hazards regression
was conducted to investigate independent predictors of
survival. Variables were entered in the multivariable
model when the P value was less than 0.05 in univariate
Cox analysis and have complete follow up information.
The median survival time was calculated using the
Kaplan–Meier method. In order to present survival dis-
tribution by significant variables, survival curves were
generated using the Kaplan–Meier method. Generally,
p < 0.05 (two-sided) was considered statistically signifi-
cant. Statistical analyses were performed with SPSS ver-
sion 16.0 (SPSS, Chicago, Illinois, USA).
Results
Analysis of the records from the past 13 years in the
pathology database of our hospital revealed that only 8
patients with histologically documented prostate cancer
with rectal involvement fulfilled the inclusion criteria.
After reviewing all medical records, 3 patient was ex-
cluded since pathology revealed prostate sarcoma, squa-
mous cell carcinoma, small cell carcinoma respectively.
The remaining 5 patients were eligible for the review of
the prostate cancer with rectal involvement. After
reviewing the 35 articles previously described in “Patient
population,” we found 22 suitable articles with clinical
description of prostate cancer with rectal involvement.
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[7-10,13-20] (with 28 cases) were in English, 5 in Japanese
[21-25] (with 7 cases), and 2 in Portuguese Language
[26,27] (with 2 cases), with a total of 37 cases being identi-
fied. We also found 3 review articles in Japanese [28-30]
(with 47 cases). Thus, 89 cases of prostate cancer invading
rectum were identified from the literature. Altogether, data
on 94 prostate cancer patients with rectal involvement were
gathered for further analysis.
The clinical characteristics of the 5 patients enrolled
from our institute are summarized in Table 1. The clin-
ical characteristics of the 94 patients are presented in
Table 2. The typical rectal biopsy and image findings of
prostate cancer invading rectum was showed in Figures 1
and 2 respectively.
At diagnosis, a high proportion of patients (63.77%)
showed extrarectal PCa metastases, and PCa with rectal
involvement only were found only in 25 (36.23%) cases.
21 patients (22.3%) were misdiagnosed preoperatively as
rectal cancer, concomitant rectal and prostate cancer, or
bladder cancer in 16, 3 and 2 patients respectively.
The appropriate treatment was given on an individual
basis according to the severity of the clinical symptoms,
preoperative diagnosis, organs involved, hormonal status
at diagnosis of rectal involvement, patient's age and
patients’ preferences. 19 of these patients (20.2%) have
accepted diverting colostomy for rectal occlusion. Treat-
ment of primary prostate cancer for the patients in the hor-
mone relapsed group consisted of hormonal therapy, either
with luteinizing hormone-releasing hormone (LHRH) ago-
nists or orchiectomy or combined with antiandrogens. 1
patient underwent TURP, and 7 patients received radical
prostatectomy or curative radiation therapy. After diagnosis
of rectal involvement at hormonally relapsed disease, 3 pa-
tients were given chemotherapy. 4 of these patients re-
ceived palliative radiotherapy due to rectal bleeding or local
pain, 1 patient received total pelvic extenteration (TPE) and















1 65 Y/N/N/N 20 S I
2 65 Y/N/N/N 124.5 S II
3 68 Y/N/N/N 3.98 M III
4 80 N/N/N/Y 1050 S I
5 58 N/N/N/N 92.41 S II
Y Yes; N no; RI: rectal involvement; DOD: dead of disease; AWD: alive with disease;
diagnosis of rectal involvement; PD = poorly differentiated; MD: moderately differen
literature [11,12].Type I means anterior rectal mass; Type II means annular rectal str
metastasis to rectum.rectum because of misdiagnosis as a carcinoma of the
rectum.
All of the 63 patients with hormone-untreated prostate
cancer were treated with hormonal therapy, either with
luteinizing hormone-releasing hormone (LHRH) ago-
nists or orchiectomy or combined with antiandrogens.
Among these who underwent hormonal therapy, part of
the patients (31.7%) also underwent different types of
local therapy, 12 of these patients were given TPE, 9 pa-
tients received radiotherapy and rectum resection were
given because of misdiagnosis as a carcinoma of the rec-
tum. Among the 12 patients who underwent TPE, 2 died
of prostate cancer at 51 and 81 months respectively, 2
died of other disease at 1 and 70 months respectively.5
patients were still alive with disease-free status for
8,10,24,36 and 96 months; 3 patients were still alive with
biochemical or clinical progression at 13,13 and 45
months. Interestingly, TPE combined hormonal therapy
give us six of thirteen long-term survivors for more than
3 years in this series. Surprisingly, most of these diseases
were extrarectal disease, only 1 with rectum only disease.
In addition, 6 patients underwent neoadjuvant and adju-
vant hormonal therapy, while another 7 patients received
adjuvant hormonal therapy.
Of the 94 patients included, data was available on the
survival status of 87 patients. The data and the hazard
ratios with overall survival of demographics, clinical
characteristics, tumor characteristics, treatment for all
the 87 cases are shown in Table 3.
11 patients in the group of synchronous rectal involve-
ment at first cancer diagnosis (n = 58) and 23 patients in
the group of metachronous diagnosis of rectal involve-
ment (n = 29) died at the latest follow up. Since more
than half of the patients are still alive it is not possible
to calculate survival accurately, but it is estimated by the
Kaplan-Meier method that the median overall survival
after diagnosis of rectal involvement will be about













PD N Y Y DOD/48
PD Y N Y AWD/18
PD Y Y N DOD/1
MD Y N Y DOD/30
PD N Y Y AWD/62
S Synchronous rectal involvement at first cancer diagnosis; M Metachronous
tiated; Type of RI was defined according to the criteria described in the
icture; Type III means ulcerating anterior rectal mass; Type IV means separate
Table 2 Clinical characteristics of 94 prostate cancer






























Japan 46 16 62
USA 4 7 11
China 4 1 5
Brazil 2 0 2
France 0 1 1
Qatar 1 0 1
Pathological grade
of RI













Mixed type 4 2 6
Tumor extent at
diagnosis of RI




ND 15 10 25
Prior therapy





TURP 0 4 4
Type of rectal
involvement
I 7 2 9
II 34 10 44
III 8 4 12
IV 3 8 11
ND 12 6 18
Table 2 Clinical characteristics of 94 prostate cancer
patients with rectal involvement (RI) (Continued)
Clinical symptoms
Dysuria 14 4 18
Dyschezia 47 17 64
Hydronephrosis 14 3 17
Rectum bleeding 14 9 23







colostomy 9 10 19
TPE 11 1 12
RR 6 3 9
RT 9 4 13
HT 63 3 66
chemotherapy 0 3 3
TPE + HT@ 12 0 12
(RR or RT or TURP)
+ HT
12 0 12
Values are given as median (min-max) or absolute numbers (number
of patients).
ND, not documented; RI, rectal involvement; TURP, transurethral resection; TPE,
HT, hormone therapy; RT, radiotherapy; RR, rectum resection
# PSA at rectal involvement (ng/ml) were available in 38 patients with
synchronous and 16 patients with metachronous diagnosis.
& Interval between primary tumor diagnosis and rectal involvement were
available in 25 patients.
*Before therapy, patients were misdiagnosized as rectal cancer, concomitant
rectal and prostate cancer, and bladder cancer in 16, 3 and 2
patients respectively.
@ 4 patients were given neoadjuvant HT + TPE + adjuvant HT
“Mixed type” means prostate adenocarcinoma mixed with signet ring cell or
ductal adenocarcinoma or papillary carcinoma.
Wang et al. Diagnostic Pathology 2014, 9:35 Page 4 of 11
http://www.diagnosticpathology.org/content/9/1/35survival rate (% ± SE) at 1, 3, and 5 years were 68.3 ± 5.3%,
54.4 ± 7.2%, and 38.1 ± 11.1%, respectively (Figure 3a). The
univariate associations between overall survival and the
clinical characteristics are summarized in Table 3 and
Figure 3b-e.The results of the multivariate analysis are
shown in Table 4. In Cox univariate analysis, Asian prostate
cancer (p = 0.001) was associated with better survival, while
rectal bleeding (p = 0.043), metachronous presentation of
development of rectal involvement (p = 0.000), prior hor-
monal therapy (p = 0.000) and extrarectal metastases (p =
0.054) were associated with poor survival. Other variables
were not significantly associated with survival. In multivari-
ate analysis, prior hormone therapy (HR = 14.540, 95% CI
5.978-35.361; p = 0.000) and rectal bleeding (HR = 2.195,
95% CI 1.035-4.655; p = 0.041) retained independent poor
prognostic values.
Figure 1 Rectal biopsy figures show typical prostate cancer with rectal involvement. a and b. Specimens of rectal biopsy show poorly
differentiated adenocarcinoma infiltrating rectal mucosa (hematoxylin-eosin, original magnification × 40 and × 400). c. Immunohistochemical
staining with anti-PSA antibody, showing that tumor cells were positive while normal colonic glands were negative (original magnification × 400);
d. Immunohistochemical staining with anti-CEA antibody, showing that tumor cells were negative while normal colonic glands were positive
(original magnification × 400).
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Prostate cancer is the second most common cancer in
men with metastasis commonly occurring in the bones
[6]. Advanced prostate cancer may spread out of the
prostate and involve adjacent pelvic organs, such as the
seminal vesicle, urinary bladder, and rectum. Of these,
the rectum is the least commonly involved by prostate
cancer. Rectal involvement, by direct invasion or metas-
tasis, occurs in 1.5% to 11% of those with prostate
cancer [11,12,31,32]. The possible reason for rectal in-
volvement may be related to tumor’s biological behavior
such as gene aberration or tumor dedifferentiation, posi-
tive surgical margin or collision tumour in the very rare
situation [33-35]. The infrequent spread to the rectum
despite its close proximity to the prostate gland has been
attributed to Denonvilliers’ fascia, a critical barrier to
local extension of tumor [36,37]. The studies dealing
specifically with rectal involvement from prostate cancer
are rare and have not been well reported. To our know-
ledge, this is the first report to investigate predictive fac-
tors of survival in prostate cancer with rectal
involvement. The results of our study are thus important
for physicians to guide treatment selection and to
counsel patients about their long-term outlook in pros-
tate cancer with rectal involvement.The diagnosis of prostate cancer with rectal involve-
ment is easily made by rectal examination, radiologic
characteristics, and especially histological examination of
the rectal biopsy in conjunction with the level of pros-
tate specific antigen. However, occasionally, prostate
cancer with rectal involvement may be confused with a
primary rectal carcinoma because of similar radiologic
appearances and clinical presentations such as large-
bowel obstruction and rectal bleeding, etc. Correct diag-
nosis is essential since the treatment and prognosis of
these two entities vary significantly. In the present study,
21 patients (22.34%) were misdiagnosed preoperatively
as rectal cancer, concomitant rectal and prostate cancer,
or bladder cancer in 16, 3 and 2 patients respectively.
The definitive diagnosis was finally established by postoper-
ative histopathological work-up. In these cases, the
preoperative misdiagnosis poses the therapeutic decision-
making a greatest problem. Although the levels of PSA,
radiographic appearance, and clinical presentation may be
helpful in distinguishing the two entities, histological exam-
ination of the lesion may be the only method of making the
correct diagnosis. It may be difficult to differentiate rectal
adenocarcinoma from prostatic adenocarcinoma in small
rectal biopsy specimens, although it is generally not a prob-
lem in operation specimens [38,39]. The morphological
Figrue 2 Typical images show prostate cancer invading rectum. a. Pelvic MRI showed a circumferential thickening of the rectum, although
there was no continuity between prostate and rectum; b. Pelvic MRI showed a protruding anterior rectal mass which compressed the rectal
lumen and continuity between prostate and rectum; c. CT of the abdomen and pelvis showed an irregular thickening of the rectum and
continuity between prostate and rectum.
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crosis, tall columnar cells with basally located nuclei, mucin
production, villous architecture and stromal inflammation.
When a definitive diagnosis cannot be established on the
basis of morphological characteristics, immunohistochemi-
cal studies can be helpful. Rectal adenocarcinoma, unlike
prostatic adenocarcinoma, shows positive staining for b-
catenin, caudal-related homeobox 2 (CDX2) and carci-
noembryonic antigen(CEA) but negative staining for PSA,
PSAP, P501S [40,41].
Traditionally, prostate carcinoma presenting with rec-
tal involvement represents an advanced stage of a highly
invasive form of the disease. The prognosis is poor. Bow-
rey et al. retrospectively described the outcome of six
prostate cancer patients with rectal infiltration and
reviewed the literature for 1966–2002. The median sur-
vival for the 86 patients with outcome data reported was
15 months (95% CI 14–16 months). Survival beyond 30
months was rare [10]. While, in the present study,
Kaplan-Meier analysis estimated that the median overall
survival was 48 months. There were 13 patients survived
for more than 3 years, the longest survival time was 96
months. This apparent discrepancy from previously pub-
lished data may be attributed to distinction rarely madeaccording to the hormonal status at presentation, differ-
ent follow up time, race differences of prostate cancer,
also advancement of treatment and diagnosis.
As expected, hormonal status at presentation had a
major impact on overall survival in PCa patients with
rectal involvement on both univariate and multivariate
analysis. In the present study, patients previously un-
treated by hormones had a relatively good prognosis
with an estimated median survival of 70 months (95%
CI, 33.154-106.847), the estimated 1, 3, 5 year survival
rate were 88.9%, 78.6% and 55.0%, respectively, and half
of them were still alive at the latest follow-up, which is
at least equivalent to patients presenting with minimal
or extensive metastatic prostate cancer treated with an-
drogen deprivation in large series [42]. Patients present-
ing with hormone relapsed disease had a much poorer
outcome with a median survival of 5 months (95% CI,
3.456-6.544). Therefore, rectal involvement does not ne-
cessarily predict a worse outcome when presented as
hormone untreated disease; when presented as a hormo-
nally relapsed disease, prognosis was worse. The possible
reason is that those with previous hormonal therapy
have no or few effective options left after RI occurs. In
the context of an increasing pipeline of novel approved
Table 3 Demographics, clinical and tumor characteristics, treatment modalities associated with overall survival by Cox
univariate analysis in 87 patients
n (%) or mean ± SD Hazard ratio (95% confidence interval) p value
Age 72.04 ± 8.427 1.044(0.998-1.093) 0.063
Grouped by age
<73 37(44.58%) 1
≥73 46(55.42%) 1.521(0.696-3.326) 0.293
Race
Non-Asian 24(27.59%) 1




Yes 17(19.54%) 0.904(0.389-2.104) 0.786
Dysuria
No 69(79.31%) 1
Yes 18(20.69%) 1.939(0.783-4.805) 0.815
Dyschezia
No 27(31.03%) 1
Yes 60(68.97%) 1.193(0.557-2.556) 0.650
bowel obstruction
No 80(91.9%) 1
Yes 7(8.1%) 0.821(0.292-2.310) 0.709
Rectum bleeding
No 67(77.01%) 1
Yes 20(22.99%) 2.145(1.023-4.498) 0.043
The Time to development of RI
Synchronous presentation 58(66.67%) 1
Metachronous presentation 29(33.33%) 14.339(5.719-35.952) 0.000
Tumor characteristics at diagnosis of rectal involvement
Pathological grade of RI
well or moderately differentiated 12(17.14%) 1
poorly differentiated 58(82.86%) 2.048(0.474-8.853) 0.337
Histology of prostate cancer RI
adenocarcinoma 81(93.10%) 1
Mixed type 6(6.90%) 0.356(0.048-2.615) 0.310
CEA
<5 ng/mL 26(83.87%) 1
≥5 ng/mL 5(16.13%) 2.795(0.510-15.331) 0.237
CA199
<37 u/mL 23(85.19%) 1
≥37 u/mL 4(14.81%) 2.150(0.223-20.768) 0.508
PSA 464.74 ± 1189.28 1.000(0.998-1.000) 0.499
PSA
<92.41 u/mL 28(52.83%) 1
≥92.41 u/mL 25(47.17%) 0.136(0.153-1.248) 0.122
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Table 3 Demographics, clinical and tumor characteristics, treatment modalities associated with overall survival by Cox
univariate analysis in 87 patients (Continued)
Type of rectal involvement
Type I 9(13.04%) 1
Type II 40(57.97%) 0.494(0.151-1.615) 0.244
Type III 11(15.94%) 1.163(0.311-4.346) 0.822
Type IV 9(13.04%) 1.653(0.433-6.304) 0.462
Hormonal status
No prior hormonal therapy 61(70.11%) 1
Prior hormonal therapy 26(29.89%) 14.658(6.042-35.561) 0.000
Tumor extent at diagnosis of RI
rectum-only 24(35.82%) 1
Extrarectal metastases 43(64.18%) 2.618(0.984-6.961) 0.054
RI: rectal involvement.
Type of RI was defined according to the criteria described in the literature [11,12].
CEA and CA199 were analyzed as categorical variables using normal value as cut off; Age and PSA were analyzed as categorical variables using median value as
cut off.
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agents (radium-223, MDV-3100), optimal survival will
probably be realized by the sequential utilization of sev-
eral different classes of agents.
Rectal involvement comprises a multitude of differing
clinical presentations. Unless one patient present asymp-
tomatic during a routine screen for occult metastases, all
other patients present with specific symptoms. In our
series, patients presented with rectal bleeding had sig-
nificantly poor survival on univariate analysis (p = 0.043).
Furthermore, the presence of rectal bleeding is an inde-
pendent prognostic factor predicting for worse prognosis
(HR 2.195, p = 0.041). It is unclear whether the tumors
of patients presenting with rectal bleeding have a differ-
ent biology. Bleeding may indicate tumors of larger lu-
minal surface, erosions, or highly vascular tumors.
An interesting finding from this study is that Asian pa-
tients appeared to predict better overall survival than non-
Asian patients on univariate analysis (p = 0.001). The results
support a previous report that many Asian prostate cancer
patients had better survival than whites [43]. The survival
advantage for Asian patients may be due to factors not
measured in our study, such as endogenous hormone
levels, dietary factors, or body composition. Further re-
search is needed to identify which, if any, of these factors
may explain these obscure findings for Asian men. All these
factors are particularly difficult to study because it is un-
clear, for example, which of the dozens of hormones in-
volved in testosterone metabolism should be measured,
and at what age to measure. Understanding the potential
interactions of each of these factors will be critically import-
ant for the development of effective prevention strategies.
Rectal involvement are often a sign of more wide-
spread systemic disease, considering the sixty-four per-
cent of patients had extrarectal metastases at thediagnosis of rectal involvement. Patients with extrarectal
metastasis disease were associated with poor overall sur-
vival in comparison with patients who had singly rectal
involved disease (Log Rank, p = 0.041; Cox, p = 0.054).
Multivariate analysis was not performed because of the
incomplete follow up information for this covariate, so
whether it is an independent prognostic factor deserves
further evaluation. However, Stage IV subcategory has
been identified as independent predictor of overall sur-
vival in stage IV prostate cancer [44]. Prostate cancer
patients with stage cT4N0M0 had significantly better
overall survival on multivariate analysis compared with
stageTxNxM1 patients (p < 0.001).
The role of curative surgery in treating prostate cancer
patients with rectal involvement has been controversial.
Historically, TPE has been generally unsuccessful when
used as a curative approach to treat locally advanced
prostate cancer in several small-sample case series and
the role of TPE was limited to palliate debilitating peri-
neal pain and other local symptoms, such as haematuria,
urinary obstruction, and urinary and rectal incontinence
[45]. Spaulding and Whitmore reported no long-term
survivors among patients with locally advanced prostatic
adenocarcinoma involving the rectums who were treated
with total pelvic exenteration [46]. Similarly, Zincke re-
ported on 7 patients who underwent total pelvic exen-
teration after failure of radiation therapy [47]. Despite
the extensive local procedure, the residual cancer rate
was high and local control was not improved with a me-
dian time to progression of 15 months. Many articles
have cited these findings and advocated a less invasive
treatment such as external beam radiotherapy [45,48]. In
this retrospective series, for the hormonally untreated
patients, there were three treatment strategies based on




Figure 3 Kaplan-Meier estimates of overall survival (a) and stratified according to (b) hormonal status (Log Rank, p = 0.000); (c) tumor
extension (Log Rank, p = 0.041); (d) race differences (Log Rank, p = 0.000); (e) time to development of rectal involvement (Log Rank,
p = 0.000); and (f) rectal bleeding (Log Rank, p = 0.036).
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have been treated with combining hormonal therapy
with radiotherapy or rectum cancer operation because of
the misdiagnosis as rectum. Surprisingly, the remaining
12 patients were given TPE (19.67%). The comparison of
survival differences between the three treatment groups
could not be done because of the high censoring rate with
short follow up in these patients.However, interestingly, in
this series, TPE combined with hormonal therapy in 12 pa-
tients give us six of thirteen long-term survivors for morethan 3 years with the longest survival time of 96 months.
Furthermore, 5 patients were still alive with disease-free
status for 8, 10, 24, 36, 96 months. The above observations
indicated that TPE combined with hormonal therapy ap-
pears to confer better survival for hormonally untreated
prostate cancer patients with rectal involvement.It is also
important to note that 9 of the 12 had extrarectal metasta-
ses at the time of surgical resection. This indicated that
extrarectal spread of disease is not a contraindication to
TPE and that such patients may also attain long-term
Table 4 Multivariable analysis with Cox regression
model to determine independent prognostic factors









Prior hormone therapy (Yes versus No) 14.540(5.978-35.361) 0.000
Rectal bleeding (Yes versus No) 2.195(1.035-4.655) 0.041
Country (Asian versus Non-Asian) 0.187
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potential survival benefit in hormonally relapsed prostate
cancer with rectal involvement only disease, because a
study [45] showed the median overall survival time of 24
months comparing with 5 months of this series. What is
the underlying reason for TPE to improve survival in pros-
tate cancer patients with rectal involvement? The possible
explanation is local control, removing the potential source
of future metastases, and improving the response to sys-
temic therapy [44]. Although it is inappropriate to make in-
ferences regarding the role of TPE in the management of
prostate cancer with rectal involvement based on the find-
ings in this retrospective review, we and others [49] believe
that TPE should be further evaluated as treatment strat-
egies for selected patients, especially in nonextrarectal
metastatic hormonally untreated patients, because they
may provide better local control and a potential long-term
survival and cure.
This study had several limitations. Due to the extreme
rarity of prostate cancer with rectum involvement, we
could obtain the data for only 5 patients who were ad-
mitted over the last 13 years to our hospital. Hence, we
collected all available cases from the literature and found
an additional 89 cases. Because of the retrospective na-
ture of data collection, the limited information provided
in the literature, and short follow-up period with high
censoring rate, the statistical results should be inter-
preted cautiously. Therefore, the absence of association
of some factors with survival could be attributed to the
small case numbers which may result in insufficient statis-
tical power. Nevertheless, the findings of this study are still
valuable for better understanding the disease processes of
prostate cancer with rectal involvement and the factors af-
fecting the survival of patients with this rare disease.
In conclusion, our findings suggest that rectal involve-
ment does not necessarily predict a worse outcome
when presenting as a previously hormone-untreated dis-
ease and that the prognosis was worse when presenting
as a hormonally relapsed disease. Although limited by
the short follow-up period with high censoring rate, our
study indicates that prior hormone therapy and rectal
bleeding were independently associated with asignificantly poor overall survival in prostate cancer pa-
tients with rectal involvement. TPE combined with hor-
monal therapy appears to confer better overall survival
in hormonally untreated patients. It is also necessary to
determine who can benefit from TPE for prostate cancer
with rectal involvement patients.
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